These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 19898279)

  • 1. Cost-effectiveness of alternative approaches to the management of chronic obstructive coronary artery disease.
    Amin AP; Cohen DJ
    Rev Cardiovasc Med; 2009; 10 Suppl 2():S3-13. PubMed ID: 19898279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic outcomes of treatment strategies for type 2 diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial.
    Hlatky MA; Boothroyd DB; Melsop KA; Kennedy L; Rihal C; Rogers WJ; Venkitachalam L; Brooks MM;
    Circulation; 2009 Dec; 120(25):2550-8. PubMed ID: 19920002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of strategies in coronary artery disease.
    Scudeler TL; Rezende PC; Hueb W
    Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):805-13. PubMed ID: 25269456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing cost aspects of coronary artery bypass graft surgery with coronary artery stenting.
    Birim Ö; Bogers AJ; Kappetein AP
    J Cardiovasc Surg (Torino); 2012 Oct; 53(5):641-50. PubMed ID: 22252542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Annual cost of stable coronary artery disease in France: A modeling study.
    Caruba T; Chevreul K; Zarca K; Cadier B; Juillière Y; Dubourg O; Sabatier B; Danchin N
    Arch Cardiovasc Dis; 2015 Nov; 108(11):576-88. PubMed ID: 26433733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resource allocation for chronic stable angina: a systematic review of effectiveness, costs and cost-effectiveness of alternative interventions.
    Sculpher MJ; Petticrew M; Kelland JL; Elliott RA; Holdright DR; Buxton MJ
    Health Technol Assess; 1998; 2(10):i-iv, 1-176. PubMed ID: 9812243
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness analysis for surgical, angioplasty, or medical therapeutics for coronary artery disease: 5-year follow-up of medicine, angioplasty, or surgery study (MASS) II trial.
    Vieira RD; Hueb W; Hlatky M; Favarato D; Rezende PC; Garzillo CL; Lima EG; Soares PR; Hueb AC; Pereira AC; Ramires JA; Kalil Filho R
    Circulation; 2012 Sep; 126(11 Suppl 1):S145-50. PubMed ID: 22965975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Percutaneous coronary intervention "dominates" coronary artery bypass graft surgery for high-risk patients: good news for patients, a challenge for healthcare planners.
    Radford MJ
    Circulation; 2006 Sep; 114(12):1229-31. PubMed ID: 16982950
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Eisenstein EL; Leon MB; Kandzari DE; Mauri L; Edwards R; Kong DF; Cowper PA; Anstrom KJ;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1199-207. PubMed ID: 20129546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of coronary revascularisation.
    Birim O; Bogers AJ; Kappetein AP
    EuroIntervention; 2010 Feb; 5(7):763-7. PubMed ID: 20142188
    [No Abstract]   [Full Text] [Related]  

  • 11. Economic outcomes of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with left main or three-vessel coronary artery disease: one-year results from the SYNTAX trial.
    Cohen DJ; Lavelle TA; Van Hout B; Li H; Lei Y; Robertus K; Pinto D; Magnuson EA; Mcgarry TF; Lucas SK; Horwitz PA; Henry CA; Serruys PW; Mohr FW; Kappetein AP
    Catheter Cardiovasc Interv; 2012 Feb; 79(2):198-209. PubMed ID: 21542113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Can PCI with drug-eluting stents replace coronary artery bypass surgery? A comparative economic analysis regarding both therapeutic options based on clinical 12-month data reflecting the German social health care insurance system].
    Fricke FU; Silber S
    Herz; 2005 Jun; 30(4):332-8. PubMed ID: 15965811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of paclitaxel-coated balloon angioplasty and paclitaxel-eluting stent implantation for treatment of coronary in-stent restenosis in patients with stable coronary artery disease.
    Bonaventura K; Leber AW; Sohns C; Roser M; Boldt LH; Kleber FX; Haverkamp W; Dorenkamp M
    Clin Res Cardiol; 2012 Jul; 101(7):573-84. PubMed ID: 22350752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surgical Revascularization versus Percutaneous Coronary Intervention and Optimal Medical Therapy in Diabetic Patients with Multi-Vessel Coronary Artery Disease.
    Giustino G; Dangas GD
    Prog Cardiovasc Dis; 2015; 58(3):306-15. PubMed ID: 26255239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of bypass surgery versus stenting in patients with multivessel coronary artery disease.
    Yock CA; Boothroyd DB; Owens DK; Garber AM; Hlatky MA
    Am J Med; 2003 Oct; 115(5):382-9. PubMed ID: 14553874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One-year clinical results and total costs of drug-eluting stents implantation in multivessel coronary artery disease.
    Varani E; Balducelli M; Vecchi G; Aquilina M; Maresta A
    J Cardiovasc Med (Hagerstown); 2007 Aug; 8(8):596-601. PubMed ID: 17667030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of the real-world use of drug-eluting stents at 9-month follow-up: results from the Sicilian DES Registry.
    Tamburino C; Barbagallo R; Capodanno D; di Matteo S; Colombo GL; Recchia M; Ciriminna S;
    J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):322-9. PubMed ID: 19430343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ten-year outcomes of patients randomized to surgery, angioplasty, or medical treatment for stable multivessel coronary disease: effect of age in the Medicine, Angioplasty, or Surgery Study II trial.
    Rezende PC; Hueb W; Garzillo CL; Lima EG; Hueb AC; Ramires JA; Kalil Filho R
    J Thorac Cardiovasc Surg; 2013 Nov; 146(5):1105-12. PubMed ID: 22944095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with 3-vessel or left main coronary artery disease: final results from the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial.
    Cohen DJ; Osnabrugge RL; Magnuson EA; Wang K; Li H; Chinnakondepalli K; Pinto D; Abdallah MS; Vilain KA; Morice MC; Dawkins KD; Kappetein AP; Mohr FW; Serruys PW;
    Circulation; 2014 Sep; 130(14):1146-57. PubMed ID: 25085960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of percutaneous coronary intervention versus bypass surgery from a Dutch perspective.
    Osnabrugge RL; Magnuson EA; Serruys PW; Campos CM; Wang K; van Klaveren D; Farooq V; Abdallah MS; Li H; Vilain KA; Steyerberg EW; Morice MC; Dawkins KD; Mohr FW; Kappetein AP; Cohen DJ;
    Heart; 2015 Dec; 101(24):1980-8. PubMed ID: 26552756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.